Prolonged screen time is associated with increased prevalence of sleep disorders in children.

Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may exert antimigraine properties beyond their metabolic effects []. Administration of the GLP-1RA liraglutide attenuated migraine-associated allodynia and reduced the expression of key migraine biomarkers in preclinical studies []. One clinical study has documented a positive impact of liraglutide on migraine frequency []. This observation raises the hypothesis that GLP-1 receptor activation could play a role in migraine, possibly through both weight-related metabolic effects and weight-independent mechanisms, although evidence remains limited. Semaglutide, another GLP-1RA, has demonstrated greater weight-loss and cardiovascular benefits than liraglutide [, ]. This might suggest that potential anti-migraine effects may also exist with semaglutide. Given that migraine affects 15% of the global population [], we aimed to investigate the effect of initiation of semaglutide for weight loss management on triptan use, an antimigraine medication utilized for acute treatment. We conducted a nationwide individual interrupted time series study (ITS) using real-world data from Danish pharmacy registers []. Dispensed medication was measured in defined daily doses (DDD) []. Semaglutide is available in two formulations, one indicated for type 2 diabetes and another for weight management (this latter formulation is only indicated for weight management and did not have a formal cardiovascular or MASH indication (Metabolic dysfunction–Associated Steatohepatitis) in Denmark at the time of the study) []. These two formulations have distinct identification codes, which can be differentiated in the registry. We identified all adults initiating semaglutide in its specific formulation for weight loss management between December 2022 and December 2024. Initiation was defined as the first-ever prescription of semaglutide at any dose (Table in supplement), regardless of whether patients continued treatment (intention-to-treat approach). The first dispensing date defined the index date, allowing 24-month baseline and 12-month follow-up periods. Follow-up data were available until December 2025. We excluded individuals with less than two years of baseline data and any record for pregnancy during the study period.